{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:50:43Z","timestamp":1791449443498,"version":"4.3.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Escient Pharmaceuticals"},{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13555-026-01883-y","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:16:10Z","timestamp":1787332570000},"page":"5245-5255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study"],"prefix":"10.1007","volume":"16","author":[{"given":"Shirley","family":"Dehn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Weyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3346-3891","authenticated-orcid":false,"given":"Etienne","family":"Saint-Cyr Proulx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5927-6587","authenticated-orcid":false,"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"issue":"11","key":"1883_CR1","volume":"13","author":"I Magnifico","year":"2020","unstructured":"Magnifico I, Petronio Petronio G, Venditti N, et al. Atopic dermatitis as a multifactorial skin disorder. can the analysis of pathophysiological targets represent the winning therapeutic strategy? Pharm (Basel). 2020;13(11):411.","journal-title":"Pharm (Basel)"},{"issue":"10478","key":"1883_CR2","doi-asserted-by":"publisher","first-page":"P583","DOI":"10.1016\/S0140-6736(24)02519-4","volume":"405","author":"E Guttman-Yassky","year":"2025","unstructured":"Guttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet. 2025;405(10478):P583\u201396.","journal-title":"Lancet"},{"issue":"4","key":"1883_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041498","volume":"21","author":"DO Lyons","year":"2020","unstructured":"Lyons DO, Pullen NA. Beyond IgE: alternative mast cell activation across different disease states. Int J Mol Sci. 2020;21(4):1498.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1883_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/exd.14222","volume":"30","author":"A Corbiere","year":"2021","unstructured":"Corbiere A, Loste A, Gaudenzio N. MRGPRX2 sensing of cationic compounds \u2013 a bridge between nociception and skin diseases? Exp Dermatol. 2021;30(2):193\u2013200.","journal-title":"Exp Dermatol"},{"issue":"6","key":"1883_CR5","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.jid.2017.12.029","volume":"138","author":"LA Nattkemper","year":"2018","unstructured":"Nattkemper LA, Tey HL, Valdes-Rodriguez R, et al. The genetics of chronic itch: gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch. J Invest Dermatol. 2018;138(6):1311\u20137.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1883_CR6","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.jaci.2004.05.066","volume":"114","author":"D Simon","year":"2004","unstructured":"Simon D, Vassina E, Yousefi S, Kozlowski E, Braathen LR, Simon HU. Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment. J Allergy Clin Immunol. 2004;114(4):887\u201395.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1883_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jid.2023.06.201","volume":"144","author":"T Jia","year":"2024","unstructured":"Jia T, Che D, Zheng Y, et al. Mast cells initiate type 2 inflammation through tryptase released by MRGPRX2\/MRGPRB2 activation in atopic dermatitis. J Invest Dermatol. 2024;144(1):53\u201362.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1883_CR8","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jaci.2024.07.002","volume":"154","author":"J Wollam","year":"2024","unstructured":"Wollam J, Solomon M, Villescaz C, et al. Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists. J Allergy Clin Immunol. 2024;154(4):1033\u201343.","journal-title":"J Allergy Clin Immunol"},{"key":"1883_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2026.04.021","author":"J Wollam","year":"2026","unstructured":"Wollam J, Solomon M, Villescaz C, et al. MRGPRX2 antagonist treatment prevents inflammation and disease in a mouse model of atopic dermatitis. J Invest Dermatol. 2026. https:\/\/doi.org\/10.1016\/j.jid.2026.04.021.","journal-title":"J Invest Dermatol"},{"key":"1883_CR10","unstructured":"Escient Pharmaceuticals. Escient Pharmaceuticals announces positive results from phase 1 study of EP262, a first-in-class oral MRGPRX2 antagonist for mast cell mediated disorders. 2023 [cited 2025 December 10]; Available from: https:\/\/www.escientpharma.com\/escient-pharmaceuticals-announces-positive-results-from-phase-1-study-of-ep262-a-first-in-class-oral-mrgprx2-antagonist-for-mast-cell-mediated-disorders\/."},{"key":"1883_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1406438","volume":"15","author":"TK Wong","year":"2024","unstructured":"Wong TK, Choi YG, Li PH, Chow BKC, Kumar M. MRGPRX2 antagonist GE1111 attenuated DNFB-induced atopic dermatitis in mice by reducing inflammatory cytokines and restoring skin integrity. Front Immunol. 2024;15:1406438.","journal-title":"Front Immunol"},{"key":"1883_CR12","unstructured":"Incyte Corporation. Incyte provides update on early phase MRGPRX2 and MRGPRX4 programs. 2024 [cited 2026 July 9]; Available from: https:\/\/investor.incyte.com\/news-releases\/news-release-details\/incyte-provides-update-early-phase-mrgprx2-and-mrgprx4-programs."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01883-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01883-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01883-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:00:32Z","timestamp":1791446432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01883-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1883"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01883-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"12 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Shirley Dehn, Daniel Cooper, Christian Weyer, Beatrice Ferguson, and Swetha Srinivasan were employees of Escient Pharmaceuticals, a wholly owned subsidiary of Incyte Corporation, at the time of the study. Etienne Saint-Cyr Proulx has served as an advisory board member, consultant, speaker, and\/or investigator and received honoraria and\/or grants from AbbVie, Arcutis, Arena Pharma, Aristea, Asana BioSciences, Bellus Health, Boehringer Ingelheim, Bristol Myers Squibb, CARA, Celgene, Dermavant, Eli Lilly, Galderma, GlaxoSmithKline, Incyte Corporation, Kiniksa, LEO Pharma, Neokera, Pfizer, Regeneron, Sanofi-Genzyme, Sienna, Target RWE, and UCB Pharma. Robert Bissonnette has served an advisory board member, consultant, speaker, and\/or investigator for and has received honoraria and\/or grants from AbbVie, Aclaris, Almirall, Alumis, Amgen, Apogee, Arcutis, Areteia, Artax, Attovia, BioMimetix, Bluefin, CARA Therapeutics, Clexio, Eli Lilly, Escient Pharmaceuticals, Fresh Tracks (Brickell), Incyte Corporation, Inmagene Bio, J&J (Janssen), LEO Pharma, Merck, Opsidio, Organon (Dermavant), Pfizer, Q32, RAPT Therapeutics, Sanofi-Genzyme, Sanofi Aventis, Sitryx, Target RWE, T Rex Bio, Triveni, Xencor, and Zurabio and is an employee and shareholder of Innovaderm Research.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with ethical principles from the Declaration of Helsinki, International Council for Harmonisation, and Good Clinical Practice guidelines. Protocols were approved by the institutional review board or ethics committee (Advarra, Inc., Columbia, MD, USA). All patients provided written informed consent prior to the start of the study.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}